Daniel R. Omstead, Ph.D.
President and Chief Executive Officer
Dan Omstead is President of TCM and the Funds. Dr. Omstead joined TCM in October 2000. Previously, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, he participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dr. Omstead holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Dr. Omstead is a member of the team responsible for making investments on behalf of the Funds and has overall investment decision responsibility. Dr. Omstead has over sixteen years of investment experience.
Jason C. Akus, M.B.A, M.D.
Senior Vice President, Research
Jason Akus joined TCM in July of 2001 after graduating from Tufts University. During medical school, Jason consulted for a variety of healthcare IT companies Dr. Akus holds a B.S. in Mathematics and an M.D. and M.B.A. from Tufts University.
Dr. Akus is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
Timothy Gasperoni, M.B.A, Ph.D.
Senior Vice President, Research
Tim Gasperoni joined TCM in March of 2015. Previously, he was a Senior Analyst and Founding Member of Sabby Capital, a public and private equity fund focused on biotechnology and medical devices. Dr. Gasperoni was head of Sabby’s research function and led the firm’s venture investment arm. Previously, Dr. Gasperoni was a Partner and Senior Analyst at Crosswind Investments, LLC, a spin-off of Cowen & Co that managed small- and mid-cap growth funds. During Dr. Gasperoni’s tenure at the firm, the funds outperformed their respective benchmarks by over 2500 basis points. Prior to Crosswind, Dr. Gasperoni was the Senior Analyst at Andesite, LLC, a healthcare-dedicated long-short fund. He led the firm’s research function and was responsible for all syndicate transaction. Prior to his career in financial services, Dr. Gasperoni served in consulting, operating, and scientific roles in the biopharmaceutical industry. Dr. Gasperoni holds a B.A. from Swarthmore College, an M.A. from the University of Pennsylvania, a Ph.D. in Neuroscience from UCLA, and an MBA from MIT.
Dr. Gasperoni is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
Christian M. Richard, M.S, M.B.A.
Senior Vice President, Research
Chris Richard joined TCM in March of 2015. Previously, Mr. Richard was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, Mr. Richard spent almost five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a B.S. in Cellular and Molecular Biology from Purchase College and both an M.S. in Biochemistry and an M.B.A. in Finance from NYU.
Mr. Richard is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
Henry Skinner, Ph.D.
Senior Vice President, Venture
Henry Skinner joined TCM in October of 2017. Previously, Dr. Skinner spent 7 years at Novaritis Services where he was Vice President and Deputy Head and Managing Director of the Novartis Venture Fund, leading the diligence and investments in innovative life-science companies. Prior to his roles at the Novartis Venture Fund, he was the Executive Director, Head Strategic Alliances at Novartis Institutes for Biomedical Research. Prior to working at Novartis, Dr. Skinner was the Chief Executive Officer at SelectX Pharmaceuticals, President and Chief Executive Officer at NeoGenesis Pharmaceuticals and also spent four years at Pfizer in the Technology Acquisitions and Operations group. Dr. Skinner holds a B.S. and M.S. in Biology/Biotechnology from Worcester Polytechnic Institute, an M.S. and Ph. D. in Microbiology from the University of Illinois and a Postdoctoral in Molecular and Human Genetics from Baylor College of Medicine.
Dr. Skinner is responsible for investment research and due diligence in the biotechnology, medical device and diagnostic areas and serves as a member of the team responsible for making and executing on venture investments on behalf of the Funds.
Ashton L. Wilson
Senior Vice President
Ashton Wilson joined TCM in July of 2018. Previously, he was a Vice President at Goldman Sachs & Co. in equity derivative trading within the Securities Division for 6 years. Prior to that, Mr. Wilson was an equity derivative trader at Bank of America Merrill Lynch for 5 years. Mr. Wilson holds a B.S. in Finance from Virginia Tech.
Mr. Wilson is responsible for investment research and due diligence in option trading and market analysis and serves as a member of the team responsible for making investments on behalf of the Funds.
Alan Kwan, M.B.A, Ph.D.
Vice President, Research
Alan Kwan joined TCM in June of 2014. Dr. Kwan previously was a Principal Investigator at GlaxoSmithKline, plc., where he designed and established proprietary experimental and analytical methodologies that leveraged platform technologies in oncology, immunology, haematology, antibacterials, vaccines, safety and toxicology, and other R&D units. Dr. Kwan also directed the installation and global deployment of genomics platform technologies throughout GSK R&D. Dr. Kwan holds a B.S. in Computer Science from The University of British Columbia, an M.S. in Computational Genetics from Washington University in St. Louis, a Ph.D. in Computational Genomics from Washington University School of Medicine, and an MBA from The Massachusetts Institute of Technology.
Dr. Kwan is responsible for investment research and due diligence of private and public companies in the biotechnology, medical device and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
Senior Analyst, Research
Chris Abbott joined TCM in June of 2016 as a Senior Analyst. Previously, Mr. Abbott spent 8 years at Leerink Partners where he was a Vice President on the Equity Research team covering the Healthcare IT and Healthcare Supply Chain group. Mr. Abbott’s research efforts also focused on Healthcare Strategy and Healthcare Policy during his time at Leerink. Mr. Abbott graduated from Hamilton College with a B.A. in Economics and a focus in Pre-Medical Studies.
Mr. Abbott is responsible for investment research in healthcare services and healthcare facilities companies on behalf of the Funds.
Robert Benson, CFA®, CAIA
Senior Analyst, Research
Rob Benson joined TCM in June 2016 as a Senior Analyst. Previously, Mr. Benson spent 12 years at State Street Global Advisors (SSgA) where he performed quantitative research for asset allocation, equities, and alternatives teams. Prior to that, Mr. Benson provided risk management and oversight of SSgA equity portfolio managers and also has investment management experience at Putnam Investments and Summa Capital. Mr. Benson holds a B.S. in Management Science from MIT and a M.S. in Financial Engineering from U Cal Berkeley and is a CFA and CAIA charterholder.
Mr. Benson is responsible for providing portfolio risk management reports, performance attribution, and quantitative research on behalf of the Funds.
Senior Analyst, Research
Rich Goss joined TCM in March 2018 as a Senior Analyst. Previously, Mr. Goss spent four years at Leerink Partners where he was a Vice President on the Large Pharma and Biotech Equity Research teams. Prior to that, Mr. Goss spent six years as a Healthcare Analyst at Datamonitor and four years in market research in Leerink’s MEDACorp division. Mr. Goss graduated from Cornell University with a B.A. in Biology.
Mr. Goss is responsible for investment research in biotechnology and pharmaceuticals companies on behalf of the Funds.
Pete Savitscus joined TCM in April of 2005 as Head Trader. Mr. Savitscus previously worked as Proprietary Trader with Fair Haven Capital, LLC in Boston. He also worked as Proprietary Trader with Abington Capital in Boston and at Merrill Lynch Investment Managers in New York and was a Senior Trader at Lafer Management Corporation and Head Trader with Craig Drill Capital also in New York. Mr. Savitscus graduated with a B.A. from Villanova University.
Mr. Savitscus is responsible for trading operations and technical research of potential and existing portfolio securities. Mr. Savitscus has over twenty years of equity trading experience.
Loretta Tse, Ph.D.
Loretta Tse joined TCM in July of 2015. Previously, Dr. Tse ran a biotech consulting business and worked with various venture funds and start-up companies. Prior to that, Dr. Tse was Managing Director, Technology Transfer and Industry Relations at Fred Hutchinson Cancer Research Center, where she ran an office that was responsible for protection and commercialization of research output and formation of start-up companies, was an Associate at Oxford Biosciences Partners, an early stage Life Sciences venture fund, and worked in business development at several early stage biotech companies prior to joining Oxford. Dr. Tse holds a Ph.D. in Pharmacology from Johns Hopkins School of Medicine and a B.S. in Biochemistry from University of California, Davis.
Dr. Tse is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making and executing on venture investments on behalf of the Funds.
Chief Compliance Officer and Vice President of Fund Administration
Laura Woodward joined TCM in May of 2009 as Chief Compliance Officer and Vice President of Fund Administration. Ms. Woodward is also Secretary and Treasurer of the Funds. Previously, Ms. Woodward was a Senior Manager with PricewaterhouseCoopers LLP from 1990 to 2009. Ms. Woodward received a B.A. from Lafayette College. Ms. Woodward is a Certified Public Accountant licensed in Massachusetts.
Ms. Woodward is responsible for providing support for and participating in all functions provided by the Adviser to the Funds. Ms. Woodward is responsible for the administration of the fair valuation process to the extent that the Funds have delegated that duty to the Adviser, certain adviser financial and administrative functions, financial reporting, oversight of service providers and regulatory compliance matters. Ms. Woodward is also responsible for developing procedures and policies that are reasonably designed to ensure that the Funds operate in accordance with the Funds’ registration statements.